Terms ending in 2037
Every in-force patent on Eyepoint, Inc.'s record whose computed term ends in 2037, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,253,094 | Antibodies That Target Human Protein Tyrosine Phosphatase-Beta (HPTP-BETA) and Methods of Use Thereof to Treat Ocular Conditions In force · High confidence | Eyepoint, Inc. | In force | High confidence | |
| US 10,597,452 | Methods of Treating Ocular Conditions by Administering Humanized Monoclonal Antibodies That Target Ve-Ptp (HPTP-BETA) In force · High confidence | Eyepoint, Inc. | In force | High confidence | |
| US 10,604,569 | Humanized Monoclonal Antibodies That Target Protein Tyrosine Phosphatase-Beta (Hptp-Beta / Ve-Ptp) In force · High confidence | Eyepoint, Inc. | In force | High confidence | |
| US 11,136,389 | Humanized Monoclonal Antibodies That Target Ve-Ptp (HPTP-BETA) In force · High confidence | Eyepoint, Inc. | In force | High confidence | |
| US 11,180,551 | Humanized Monoclonal Antibodies That Target Ve-Ptp (HPTP-Beta) In force · High confidence | Eyepoint, Inc. | In force | High confidence | |
| US 12,145,986 | A Method of Treating an Ocular Condition by Administering a Humanized Monoclonal Antibodies That Target Ve-Ptp (HPTP-Beta) In force · Medium confidence | Eyepoint, Inc. | In force | Medium confidence |
6 of 6 patents shown. Soonest term end first, then patent number.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.